CYTALUX targets folate receptors commonly found on many cancers, such as ovarian cancer. The imaging agents illuminate the cancerous tissue, which may enable surgeons to detect cancer that otherwise may have been left behind.ĬYTALUX, the Company's first product, received FDA approval for ovarian cancer in November 2021. Corley Distinguished Professor of Chemistry, is comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to receptors overexpressed on cancer cells. Low, PhD, Purdue University's Presidential Scholar for Drug Discovery and the Ralph C. Their molecular imaging technology, based on the pioneering work of Philip S. On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery. Intraoperative Molecular Imaging (IMI) is an emerging category of technology for surgical oncology in which targeted imaging agents are injected into patients to highlight cancer cells making them visible during surgery. To date, there have been limited ways for surgeons to confidently assess the location and full extent of cancerous tissue while operating. Information about AATS 2022 can be found at About Intraoperative Molecular Imaging "Transbronchial Lung Tumor Localization with Folate Receptor-Targeted Near-Infrared Molecular Imaging: A Proof-of-Concept Study in Animal Models," Tsukasa Ishiwata, MD, PhD, University of Toronto – Tuesday, May 17, 8:45 am ET, Room 311įor more information about On Target, visit booth 1301 during the meeting or To schedule a meeting with On Target at AATS 2022, email."Single-Cell Optical Detection of Lung Cancer in Real Time by Targeted Near-Infrared Confocal Laser Endomicroscopy Imaging," Gregory Kennedy, MD, PhD, University of Pennsylvania – Sunday, May 15, 12:30 pm ET, Room 309."Our commitment to research will help us continue advancing our mission to illuminate cancer intraoperatively to reduce the challenges with identifying cancerous tissue for removal."Īdditional presentations at AATS related to CYTALUX include: "We are proud of the breadth of studies being presented at the AATS 102 nd Annual Meeting, highlighting the significant potential we see for CYTALUX to aid in real-time, intra-procedural treatment decisions," said Chris Barys, President and Chief Executive Officer of On Target. ![]() "The ability to visualize cancer cells beyond what can be seen and felt with today's standard of care is an important step toward greater precision during surgery." "These positive Phase 3 trial results show that when surgeons used a targeted fluorescent dye to bind to cancer cells to make them glow, intraoperative molecular imaging helps better identify a patient's tumors for resection," said Singhal. This trial was performed at 11 other centers around the country including MD Anderson, Mayo Clinic, Cleveland Clinic, University of Virginia, University of Michigan, University of Pittsburgh, Swedish Cancer Institute, Stamford Hospital, University of Iowa, Allegheny Hospital, and Beth Israel Deaconess Hospital. ![]() The research findings will be presented by Sunil Singhal, MD, Director of the Center for Precision Surgery, Abramson Cancer Center at the University of Pennsylvania, and national principal investigator of the Phase 3 clinical trial, on Tuesday, May 17 at 9:30 am ET in Room 311. On Target previously announced the trial successfully achieved its primary endpoint. The late-breaking presentation will highlight outcomes of the pivotal ELUCIDATE Trial, which assessed the efficacy of CYTALUX and near-infrared imaging (NIR) to intraoperatively identify pulmonary nodules and evaluate resection margins. WEST LAFAYETTE, Ind., /PRNewswire/ - On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery, today announced that results from the randomized, multi-center Phase 3 ELUCIDATE Trial will be presented at the 102 nd American Association for Thoracic Surgery (AATS) annual meeting, May 14-17, 2022 in Boston.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |